These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 28250960)

  • 1. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    Frey MK; Pothuri B
    Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
    Ratnaparkhi R; Javellana M; Jewell A; Spoozak L
    Curr Treat Options Oncol; 2024 Feb; 25(2):237-260. PubMed ID: 38300479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    Rabban JT; Chen LM; Devine WP
    Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
    Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
    JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Sullivan MW; Graves S; Adkoli A; Zhou Q; Iasonos A; Ellenson LH; Chi DS; Aghajanian C; Liu YL; Sonoda Y; O'Cearbhaill RE; Weigelt B; Grisham RN
    Cancer; 2024 Aug; ():. PubMed ID: 39150003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Haunschild CE; Tewari KS
    Gynecol Oncol; 2021 Jan; 160(1):333-345. PubMed ID: 33055011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial Cancers in
    Smith ES; Da Cruz Paula A; Cadoo KA; Abu-Rustum NR; Pei X; Brown DN; Ferrando L; Sebastiao APM; Riaz N; Robson ME; Soslow RA; Reis-Filho JS; Mandelker D; Weigelt B
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
    Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
    Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
    Levine MD; O'Malley DM; Haight PJ; Senter L; Wagner V; Bixel KL; Cohn DE; Copeland LJ; Cosgrove CM; McLaughlin EM; Backes FJ
    Gynecol Oncol Rep; 2023 Apr; 46():101173. PubMed ID: 37082521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.